A Phase II Study of Hepalatide in Subjects With Chronic Hepatitis B

NCT04426968 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis B, Chronic

Interventions

DRUG: Hepalatide 2.1mg
DRUG: Hepalatide 4.2mg
DRUG: Hepalatide 6.3mg
DRUG: placebo 2.1mg
DRUG: placebo 4.2mg
DRUG: placebo 6.3mg
DRUG: Pegylated Interferon

Sponsor

Shanghai HEP Pharmaceutical Co., Ltd.